VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase I drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VIS-954’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VIS-954 overview

VIS-954 is under development for the treatment of ANCA-associated vasculitis and transplant rejection. The drug candidate acts by targeting C5a anaphylatoxin chemotactic receptor 1 (C5AR1). It is developed based on Hierotope platform technology. It is administered through subcutaneous route.

Visterra overview

Visterra, a subsidiary of Otsuka Holdings Co Ltd, is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company’s pipeline products include VIS410, a monoclonal antibody designed to treat influenza A, VIS513, a monoclonal antibody for the treatment of dengue and VIS649, an anti-APRIL monoclonal antibody (mAb) for the treatment of Imumuglobulin A Nephropathy (IgAN). Visterra utilizes its hierotope platform to design and engineer antibody-based therapies that target specific regions and epitopes of pathogens. Visterra is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of VIS-954’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.